Gentium S.p.A. announced today that it has been informed that the Company's Marketing Authorization Application for Defibrotide to treat and prevent hepatic veno-occlusive disease in adults and children undergoing haematopoietic stem cell transplantation therapy will be on the agenda for discussion at the European Medicines Agency's Committee for ... (more)
http://www.biospace.com/news_story.aspx?StoryID=285077&full=1
http://www.biospace.com/news_story.aspx?StoryID=285077&full=1
No comments:
Post a Comment